Why are doctors and scientists so excited about stem cells?
Stem cells have potential in many different areas of health and medical research.
Adult and embryonic stem cells differ in the type of cells that they can develop into.Embryonic stem cells can become all cell types of the body (they arepluripotent). Adult stem cells are found in mature tissues (bone marrow, skin, brain, etc.) and give rise to other cell types from their tissue or origin (they are are multipotent). For example, adult blood stem cells give rise to red blood cells, white blood cells and platelets.
Adult stem cells are thought to exist in every type of tissue in the body. But, to date, the isolation of many types of adult stem cells has been limited. Hematopoietic (blood) stem cells are readily available via bone marrow aspiration. But stem cells for solid organs such as liver or brain have proven more difficult to identify and derive. The hope is that hESCs can be used to derive every type of adult stem cell in the body and allow research that is currently not possible.
Embryonic stem cells are isolated from 3 to 5 day old human embryos at the blastocyst stage. The blastocyst is a hollow microscopic cluster of several hundred undifferentiated cells.
This is a culture of hESCs derived from a single embryo. Because stem cells can self-replicate, just a few hESCs can give rise to a whole population of identical hESCs, or a cell line.
Once established, a cell line can be grown in the laboratory indefinitely and cells may be frozen for later use or distributed to other researchers. Because each cell line has its own distinct genetic footprint, researchers are often interested in using the same cell line for a number of related experiments.
No. At this point, the promise is huge, but hESC research is still in its early stages. Human embryonic stem cell (hESC) research only began in 1998, when a group led by Dr. James Thomson at the University of Wisconsin developed a technique to isolate and grow the cells.
In late January 2009, the California-based company Geron received FDA clearance to begin the first human clinical trial of cells derived from human embryonic stem cells. View Geron press release
In contrast, research with adult stem cells such as blood-forming stem cells in bone marrow (called hematopoietic stem cells, or HSCs) has been active for over decades. And this research has resulted in treatment of patients; for example, bone marrow (stem cell) transplants have been conducted for over 40 years.
In addition, studies with a limited number of patients have demonstrated the clinical potential of adult stem cells in the treatment of other human diseases that include diabetes and advanced kidney cancer.
Induced pluripotent stem cells (iPS cells) are cells that began as normal adult cells (for example, a skin cell) and were engineered (induced) by scientists to become pluripotent, that is, able to form all cell types of the body. This process is often called 'reprogramming.' While iPS cells and embryonic stem cells share many characteristics they are not identical. Scientists are currently exploring whether they differ in clinically significant ways.
The technology used to generate iPS cells holds great promise for creating patient- and disease-specific cell lines for research purposes. These cells are already useful tools for drug development and scientists hope to use them in transplantation medicine. However, additional research is needed before the reprogramming techniques can be used to generate stem cells suitable for safe and effective therapies.
Somatic cell nuclear transfer (SCNT), is a technique in which the nucleus of a somatic cell (any cell of the body except sperm and egg cells) is injected, or transplanted, into an egg, that has had its nucleus removed. The product of SCNT has the same genetic material as the somatic cell donor.
Yes. SCNT is a technique of cloning. The product of SCNT is nearly genetically identical to the somatic cell used in the process. (Of note, the product of SCNT is not technically 100% identical in that the cytoplasm of the oocyte includes mitochondrial DNA.) While SCNT is considered cloning, it is important to differentiate between therapeutic and reproductive cloning. The following FAQ addresses these differences.
Reproductive cloning includes the placement of the product of SCNT into a uterus for the purpose of a live birth. The resulting organism would, in theory, be the genetic copy of the somatic cell donor. Reproductive cloning has been performed in animals for many years and is burdened by many technical and biological problems. Only about 1 percent of all the eggs that receive donor DNA can develop into normal surviving clones. Therapeutic cloning uses SCNT for the sole purpose of deriving cells for research, and potentially in the future for therapy. In therapeutic cloning, the product of SCNT is not placed into a uterus and hence a live birth is never a possibility. Therapeutic cloning provides two potential benefits.
Yes. Massachusetts state law that was enacted in May 2005 allows hESC research and it allows the derivation of hESCs from embryos that were created for reproductive purposes and are no longer needed for reproduction and from somatic cell nuclear transfer.
The National Academy of Sciences (NAS) issued guidelines for hESC research in April 2005, and subsequently updated those guidelines in 2007 and 2008. The current guidelines contain detailed recommendations with regard to many aspects of hESC research, including:
No. IRB approval is required for:
Until recently, the federal government limited its funding to specific hESCs derived before August 9, 2001. Specifically, federal funds were only allowed for research on hESCs listed on the National Institutes of Health (NIH) Registry, and on derivative products from hESCs on the NIH Registry. On March 9, 2009, President Obama signed an executive order clearing the way for the NIH and other federal agencies to fund research using all kinds of hESCs.
Human embryonic stem cell research at the Center for Regenerative Medicine has been supportedin partby private philanthropic donations. These donations allowed us to support a wide range of research activities that could not have been supported from other sources such as NIH funding. In the future, we expect to receive support for eligible activities from NIH and other funding agencies.
The Center for Regenerative Medicine depends upon philanthropic support. To find out how you can help accelerate research and discovery, please click here.
The Center for Regenerative Medicine is dedicated to understanding how tissues are formed and may be repaired in settings of injury. Embedded at Mass General Hospital, the Center's primary goal is to develop novel therapies to regenerate damaged tissues and thereby overcome debilitating chronic disease. The success of this effort requires a cohesive team of scientists and clinicians with diverse areas of expertise, but with a shared mission and dedication to the larger goal.
The Center for Regenerative Medicine has extensive interactions with other investigators at MGH and in the broader Harvard-MIT community. The Center helped galvanize the establishment of the Harvard Stem Cell Institute (HSCI), which is co-directed by Dr. Scadden and Dr. Douglas Melton of Harvard's Department of Stem Cell and Regenerative Biologyand the Howard Hughes Medical Institute. As an important confederated partner of HSCI, the Center brings specific features that augment other elements of HSCI, including unique stem cell clinical investigation expertise and ongoing collaborative clinical trials using stem cell transplantation. The Center emphasizes technologies that will ultimately be critical for the success of stem cell based medicine, including bioengineering, biomaterials expertise, close links to in vivo imaging capability and its GMP facility for sophisticated cell manipulation.
Excerpt from:
Stem Cell FAQ - Massachusetts General Hospital, Boston, MA
- Heres How Fasting Benefits Your Mental and Physical Wellbeing - News18 - October 4th, 2022
- Asymmetrex Gives First Cell Culture Core Facility Introduction to Online Rapid Stem Cell Counting in the Institute for Applied Life Sciences at... - September 25th, 2022
- Asymmetrex's Introduction of Online Calculators for Determination of the Dosage of Therapeutic Stem Cells Announced as a Reformation in Stem Cell... - September 16th, 2022
- UMass Dartmouth awarded $750000 Massachusetts Life Science grant to diversify the field - New Bedford Guide - September 16th, 2022
- ALS Thought Leaders Weigh in Ahead of Second Amylyx Adcomm - BioSpace - September 8th, 2022
- Scientists convert kidney to universal O blood type - Freethink - August 30th, 2022
- Case Study: SARS-CoV-2 Virus Infecting the Inner Ear - Victoria News - August 14th, 2022
- Evidence Is Growing That LSD Improves Learning and Memory - Futurism - August 14th, 2022
- Rice University: Rice, Baylor developing implants to heal heart attack injuries | India Education | Latest Education News | Global Educational News |... - August 14th, 2022
- Iconic everyday inventions and the women behind them - YourStory - August 14th, 2022
- Head to Head Analysis: VolitionRx (NYSE:VNRX) vs. Intellia Therapeutics (NASDAQ:NTLA) - Defense World - August 14th, 2022
- Man who saved life as stem cell donor urges others to help his friend find a match after five-year search - Lancashire Evening Post - August 5th, 2022
- The 3D Cell Culture Market is expected to reach a value of USD 3721.86 Million by 2027, at a CAGR of 13.4% (2021 2027) - Digital Journal - August 5th, 2022
- Flow Cytometry Market is expected to reach a value of USD 11467.80 Million by 2027, at a CAGR of 8.88% over the forecast period (2021 2027) - Digital... - July 27th, 2022
- Stem Cells Market Competitive Insights And Global Outlook 2022 To 2027 Vcanbio, Boyalife, Beikebiotech, Thermo Fisher Scientific (Massachusetts, US),... - July 11th, 2022
- Seven UMass Amherst Faculty Members Receive NSF CAREER Awards in 2021-22 Academic Year - UMass News and Media Relations - July 11th, 2022
- BrainStorm Strengthens Executive Team with Key Appointments in R&D and Legal - GuruFocus.com - June 22nd, 2022
- Asymmetrex Presents New Developments in its Rapid Stem Cell Counting Technology at the ARMI|BioFabUSA Meeting in the Millyard on Regenerative Medicine... - June 13th, 2022
- Investigators Seek to Push Combination Therapy to the Front-line Treatment of aGVHD - OncLive - June 4th, 2022
- Stem Cells Market 2022 Industry Analysis, Segmentation, Share, Size, Opportunities and Forecast to 2027 The Greater Binghamton Business Journal - The... - June 4th, 2022
- Sheldon Krimsky, Who Warned of Profit Motive in Science, Dies at 80 - The New York Times - May 15th, 2022
- We met during cancer treatments, fell in love and got married - New York Post - May 15th, 2022
- Ticking time bombs of DNA mutation may dictate when animals die - Livescience.com - May 2nd, 2022
- Sen. Orrin Hatch's legacy tracks the GOP's evolution on health - Wisconsin Public Radio - May 2nd, 2022
- Emerging interactions between skin stem cells and their ... - April 6th, 2022
- Priothera Receives R&D Innovation Loan from Bpifrance - PR Newswire - April 6th, 2022
- What is Regeneration? review: A dive into the science of regrowth - New Scientist - April 6th, 2022
- 5 FDA decisions to watch in the second quarter - BioPharma Dive - April 6th, 2022
- Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners - The New York Academy of Sciences - April 6th, 2022
- MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults... - March 25th, 2022
- January 2022: 2021 Papers of the year - Environmental Factor Newsletter - January 5th, 2022
- Liso-Cel Outperforms Standard Therapy in Improving QoL in Relapsed/Refractory LBCL - www.oncnursingnews.com/ - January 5th, 2022
- Stem cells: Sources, types, and uses - Medical News Today - December 24th, 2021
- cGVHD Paradigm Gains Systemic Options Beyond Steroids, But Real-World Data Are Required - OncLive - October 28th, 2021
- Asymmetrex Will Present a New Test for Therapeutic Stem Cell Potency at the ISSCR 2021 Annual Meeting - PRNewswire - June 23rd, 2021
- Infertility: Men account for at least half of cases. So why have women shouldered the blame? - The Irish Times - June 23rd, 2021
- On systemic sources of early life stress, and empathetic responses - MIT News - June 6th, 2021
- How Coronavirus Damages Lung Cells Within Mere Hours And What Drugs Could Halt COVID-19 Infection - SciTechDaily - February 1st, 2021
- Orchard Therapeutics Outlines Comprehensive Presence at 2021 WORLDSymposium - GlobeNewswire - February 1st, 2021
- NurOwn May Be Given to Early ALS Patients in US Who Finished Phase... - ALS News Today - December 20th, 2020
- Be Biopharma debuts with $52M to advance engineered B-cell therapies - FierceBiotech - October 24th, 2020
- Targeted Therapy for Non-Hodgkin Lymphoma: Current Progress and Future Plans - Cancer Therapy Advisor - September 5th, 2020
- Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder - Newswise - July 2nd, 2020
- Startup targets glioblastoma tumors with CAR-T therapy - FierceBiotech - May 28th, 2020
- Infrared Laser Treatment of TBI, PTSD, and Depression: An Expert Perspective - Psychiatry Advisor - April 3rd, 2020
- 10 Of The Biggest World Revelations In The 21st Century - World Atlas - February 29th, 2020
- Where Are They Now? Top 3 Biotech Startups From NextGen Bio Class of 2018 - BioSpace - January 10th, 2020
- Firm adds a new wrinkle to anti-aging products - Williamson Daily News - January 5th, 2020
- Top Emerging Technologies of the Year - Technowize - December 29th, 2019
- New Podcast Sponsored by Asymmetrex Increases Awareness to the Need for Stem Cell Dose in Stem Cell Treatments - PR Web - November 9th, 2019
- Exercise found to block chronic inflammation in mice - Harvard Gazette - November 9th, 2019
- Arkuda bags $44M to target progranulin and head off inherited dementia - FierceBiotech - November 9th, 2019
- New study reveals why breast cancer spreads to the brain - USC News - October 23rd, 2019
- Comparison of Merus N.V. (MRUS) and Sage Therapeutics Inc. (NASDAQ:SAGE) - MS Wkly - October 23rd, 2019
- Reviewing Cellectis S.A. (CLLS)'s and Magenta Therapeutics Inc. (NASDAQ:MGTA)'s results - MS Wkly - October 23rd, 2019
- Massachusetts Stem Cells | Stem Cell TV - September 10th, 2019
- Chronic variable stress activates hematopoietic stem cells ... - April 12th, 2019
- Boston, MA, Stem Cell Transplant, Weston, Nantucket ... - January 10th, 2019
- Cloning/Embryonic Stem Cells - National Human Genome ... - July 5th, 2018
- Alternate Methods for Preparing Pluripotent Stem Cells ... - September 25th, 2017
- Doubts raised about CRISPR gene-editing study in human embryos - Nature.com - September 2nd, 2017
- For Lowell native, stem cell match becomes a match as friends - Lowell Sun - September 2nd, 2017
- Lymphoma Patient's Brain Tumor Disappeared After She Received JCAR017, Study Reports - Lymphoma News Today - September 2nd, 2017
- Asymmetrex Introduces New Contract Service For Producing ... - PR Web (press release) - August 29th, 2017
- ORGANOID - Science Magazine - August 27th, 2017
- Current humanized mice not good models for studying stem cell transplants, say researchers - Scope (blog) - August 27th, 2017
- Mouse Model of Human Immune System Inadequate for Stem Cell ... - Technology Networks - August 27th, 2017
- CRISPR fixes disease gene in viable human embryos - Nature.com - August 6th, 2017
- X4 joins hands with Yale on rare disease program - FierceBiotech - August 6th, 2017
- TGF-1: ALS Astrocytes' Secret Sauce? - ALS Research Forum - August 6th, 2017
- From Stem Cells to Human Development - September 2016 ... - December 4th, 2016
- Stem cell controversy - Wikipedia - December 1st, 2016
- What Are Stem Cells? - Massachusetts General Hospital ... - November 22nd, 2016
- New England Cord Blood Bank - Cord Blood and Cord Tissue ... - November 22nd, 2016
- Stem-cell-based therapy promising for treatment of breast ... - September 26th, 2016
- Stem Cell Facts - University of Massachusetts Medical School - July 27th, 2016
- Scientists engineer toxin-secreting stem cells to treat ... - October 19th, 2015
- Cloning/Embryonic Stem Cells - Genome.gov - October 19th, 2015
- Biomedical engineer developing nanomaterial for healing broken bones - March 18th, 2015
- Researchers identify a vital protein that can determine head and brain development - March 13th, 2015